Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez SecordKirsten Bell BurdettKouros OwzarDavid TritchlerAlexander B SibleyYingmiao LiuMark D StarrJ Chris BradyHeather A LankesHerbert I HurwitzRobert S MannelKrishnansu S TewariDavid M O'MalleyHeidi GrayJamie N Bakkum-GamezKeiichi FujiwaraMatthew BoenteWei DengRobert A BurgerMichael J BirrerAndrew B NixonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel. Aligning with results observed in patients with renal cancer treated with antiangiogenic therapies, it appears plasma IL6 may also define those patients with EOC more or less likely to benefit from the addition of bevacizumab to standard chemotherapy.